MLEC
Moolec Science SA·NASDAQ
--
--(--)
--
--(--)
0.70 / 10
Underperform
Fundamental analysis reveals critical issues: ROE and annualized ROE are deeply negative at -22.67%, net profit YoY decline is a steep -241%, and cash flow to operating revenue ratio is only 1.08%. These metrics place MLEC in the lowest performance quartile, historically associated with negative returns, confirming a weak financial base that undermines investment appeal.
Analysis Checks(0/5)
Annualized return on equity (%)
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Net cash flow from operating activities / Total liabilities (%)
Value0.01
Score1/3
Weight-3.00%
1M Return0.50%
Value0.01
Score1/3
Weight-3.00%
1M Return0.50%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value-241.01
Score0/3
Weight23.74%
1M Return-4.54%
Value-241.01
Score0/3
Weight23.74%
1M Return-4.54%
Net cash flow from operating activities / Operating revenue (%)
Value1.08
Score0/3
Weight26.88%
1M Return-5.66%
Value1.08
Score0/3
Weight26.88%
1M Return-5.66%
ROE (%)
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Annualized return on equity (%)
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Net cash flow from operating activities / Operating revenue (%)
Value1.08
Score0/3
Weight26.88%
1M Return-5.66%
Value1.08
Score0/3
Weight26.88%
1M Return-5.66%
Net cash flow from operating activities / Total liabilities (%)
Value0.01
Score1/3
Weight-3.00%
1M Return0.50%
Value0.01
Score1/3
Weight-3.00%
1M Return0.50%
ROE (%)
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Value-22.68
Score0/3
Weight26.19%
1M Return-5.36%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value-241.01
Score0/3
Weight23.74%
1M Return-4.54%
Value-241.01
Score0/3
Weight23.74%
1M Return-4.54%
Is MLEC undervalued or overvalued?
- MLEC scores 0.70/10 on fundamentals and holds a Premium valuation at present. Backed by its -133.38% ROE, -52.67% net margin, -0.04 P/E ratio, -0.05 P/B ratio, and -207.17% earnings growth, these metrics solidify its Underperform investment rating.
